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Rationale: Bronchiolitis obliterans syndrome (BOS) is a late, non-infectious pulmonary complica-
tion following hematopoietic stem cell transplantation (HSCT). There is minimal data published
on quantitative radiologic characterization of airway remodeling in these subjects.
Objectives: To examine quantitative measurements of airway morphology and their correlation
with lung function in a cohort of patients who underwent HSCT and developed BOS.
Methods: All adult patients who underwent allogeneic HSCT at the Dana-Farber Cancer Insti-
tute/Brigham and Women’s Hospital (n Z 1854) between January 1st 2000 and June 30th
2010 were screened for the development of BOS. Clinically acquired high resolution CT (HRCT)
scans of the chest were collected. For each subjects discrete measures of airway wall area were
performed and the square root of wall area of a 10-mm luminal perimeter (Pi10) was calculated.
Measurements and main results: We identified 88 cases of BOS, and 37 of these patients had
available HRCT. On CT scans obtained after BOS diagnosis, the Pi10 decreased (consistent with
airway dilation) as compared with pre-BOS values (p < 0.001). After HSCT the Pi10 correlatedterans syndrome; HSCT, hematopoietic stem cell transplantation; HRCT, high resolution computed
volume in 1 s; DLCO, carbon monoxide diffusion capacity; FEV1/FVC, ratio of forced expiratory volume
; RV, residual lung volume; COPD, chronic obstructive pulmonary disease; PFTs, pulmonary function
between 25 and 75%; VC, vital capacity; IC, inspiratory capacity; ERV, end residual volume; TLC, total
ual lung volume to total lung capacity; SRWA Pi10 mm, square root of wall area of a 10-mm luminal
ter; WA%, wall area percent.
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Airway dilation in bronchiolitis obliterans 277with FEV1% predicted (rZ 0.636, p < 0.0001), and RV/TLC% predicted (rZ 0.736, p< 0.0001),
even after adjusting for age, sex and total lung capacity (p < 0.0001 for both).
Conclusions: On HRCT scan BOS is characterized by central airway dilation, the degree of which
is correlated to decrements in lung function. This is opposite of what has been previously demon-
strated in COPD and asthma that quantitative measure of proximal airway wall thickening
directly correlate with pulmonary function. Our data suggests that the pathologic process
affecting the central airways is different from the pathology observed in the distal airways.
Further work is needed to determine if such change can be used as a sensitive and specific tool
for the future diagnosis and staging of BOS.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Bronchiolitis obliterans syndrome (BOS) is a form of irre-
versible airflow obstruction and is a late, non-infectious
pulmonary complication following hematopoietic stem cell
transplantation (HSCT).1 Depending on the disease defini-
tion, the prevalence of BOS in the allogeneic HSCT pop-
ulation ranges from approximately 2%e26%.2e7 and it is
associated with a significant increase in morbidity and
mortality.3,8
The clinical presentation of BOS is usually insidious and
may include a dry cough, shortness of breath, or dyspnea on
exertion, but up to 20% of patients are asymptomatic.7 In
the absence of routine spirometric screening, reports of
disease prevalence likely underestimate the true burden of
BOS, since symptomatic patients are typically already
suffering from moderate to severe airflow obstruction.7
Published studies of high-resolution computed tomog-
raphy (HRCT) in BOS after HSCT have reported subjective
evaluations of radiographic findings.9e13 The largest study
(n Z 33) by Gunn et al.13 demonstrated that the visually
assessed degree of air trapping on expiratory high resolu-
tion computed tomographic (HRCT) scan correlated with
the forced expiratory volume in 1 s (FEV1), carbon
monoxide diffusion capacity (DLCO), ratio of forced expi-
ratory volume in one second to forced vital capacity (FEV1/
FVC), and residual lung volume (RV). There is an extensive
literature available in the CT characterization of airway
disease in other obstructive conditions, such as chronic
obstructive pulmonary disease (COPD) and asthma. There-
fore, we examined the clinically acquired data on almost
2000 patients who underwent allogeneic HSCT at our
institution to identify the subset who were diagnosed with
BOS. We hypothesized that the measurements of airway
dimensions in patients with BOS would correlate with the
degree of pulmonary dysfunction.Methods
Subjects
All patients who underwent an allogeneic HSCT at the Dana-
Farber Cancer Institute/Brigham and Women’s Hospital
(n Z 1854) between January 1st 2000 and June 30th 2010
were screened for the development of BOS. All pulmonary
function tests (PFTs) conducted between January 1st 2000
and June 30th 2010 were reviewed for the presence ofexpiratory airflow obstruction (FEV1/FVC ratio 0.7).
Patients identified as having an FEV1/FVC ratio 0.7 either
before or after HSCT then underwent a detailed chart review
and were excluded if they had reversible airflow obstruction
or an alternative explanation for their obstructive deficit.
From this remaining cohort, BOSwas defined as (1) newonset
airflow obstruction, FEV1/FVC ratio 0.7 and FEV1 < 80%
predicted; (2) irreversible obstruction definedas no response
to bronchodilator per ATS criteria14; (3) if airflow obstruction
was noted prior to HSCT, a 15% decline in FEV1 from base-
line; or (4) BO confirmed by pathology irrespective of
meeting the spirometric definition of BOS.
Control subjects were identified from the same patient
population and were included in the study if they had pre
and post transplant pulmonary function testing demon-
strating no significant change in pulmonary function per ATS
criteria14 and a pre and post transplant non-contrast HRCT
scan available for analysis.
The medical records of all subjects meeting criteria for
BOSwere examined for bothmeasures of pulmonary function
and high resolution CT (HRCT) scans of the chest. All PFTs
were performed according to the American Thoracic society
guidelines.14 For correlative studies, CT scans and PFTs were
used if they were within 30 days of each other. Lung function
data collected included FEV1, FVC, forced expiratory flow
between 25 and 75% (FEF25e75), vital capacity (VC), inspira-
tory capacity (IC), end residual volume (ERV), total lung
capacity (TLC), RV, DLCO and the ratios of RV to TLC (RV/TLC)
all expressed as a percentage of predicted values. FEV1/FVC
is expressed as a ratio.14 Lung volumes were assessed using
He dilution or plethysmography.CT scans
All CTscanswereperformed for routineclinical careandwere
included in this investigation if they had sufficient high-
resolution images for analysis. Scans were obtained with the
patient supine during full inspiration with or without intra-
venous contrast enhancement. Images were reconstructed
using a high spatial frequency algorithm with 1.00e1.5-mm
slice thickness at 10e20 mm intervals. Discrete measures of
airway wall area were performed in a total of 16 randomly
selected airways with 4 in each quadrant; (ie, the right and
left upper and lower lobes) using Airway Inspector (www.
airwayinspector.org). From these measures, the square root
of wall area of a 10-mm luminal perimeter (SRWA Pi10 mm)
was calculated.15,16 The Pi10 is derived by plotting the square
root of airwaywall area vs. theairway lumenperimeter. From
278 L. Gazourian et al.this plot, one can derive the SRWA of a theoretical airway of
standard lumen size (i.e. 10 mm lumen circumference) from
a number of different airway sites. This single measure then
represents a single quantitative assessment of airway
remodeling for each subject Fig. 1.
Patients with a Pre-BOS and Post BOS HRCT which
allowed for direct anatomical matching of pre and post
airways we measured lung volume, wall thickness, internal
lumen perimeter (PI), and wall area percent (WA%) using
Airway Inspector (www.airwayinspector.org). WA%: A
commonly reported CT based metric of airway morphology
reported in both the COPD and asthma literature. It is
calculated as 100*wall area/total bronchial area.16,17 CT
based measures of lung volume were calculated as
described previously.18
The presence of bronchiectasis, mosaic attenuation,
ground glass opacities, centrilobular nodules or nodules and
bronchial wall thickening was recorded from the clinical
reports for all HRCT scans used in our analysis.
For correlative studies both pre and post diagnosis BOS
HRCT scans were analyzed if there was a corresponding PFT
within 30 days of the HRCT scan. If multiple HRCT scans were
availablewithin30days of PFTs, theoneclosest to thedateof
PFT was utilized. For longitudinal studies, HRCT scans were
included if the patient had at least twoHRCTscans available.
A pre diagnosis HRCT scan was defined as being conducted
prior to transplantation or after HSCT but >120 days before
the diagnosis of BOS. A post diagnosis HRCT scan was defined
as being obtainedpost diagnosis orwithin 60 days of diagnosis
of BOS, only non-contrast HRCT scans were included in the
correlative analysis. Within the cohort of subjects for the
longitudinal analysis contrast enhanced scans were included
in the analysis only if both the baseline and follow up scan
were acquired in this fashion.
This study was approved by the Institutional Review
Board at Dana Farber Cancer Institute/Harvard Cancer
Center, Boston, MA.Statistical analysis
Data are presented as medians. Univariate analysis was
performed to investigate the relationship between CT
measures of airway remodeling and both spirometry andFigure 1 Methods for airway measurements.more detailed measures of lung function. Results are pre-
sented as Spearman correlation coefficients. Additional
multivariate regression analysis was performed to further
investigate the association between CT assessed airway
morphology and lung function. These models were adjusted
for age, sex, and lung volume (obtained from either
plethysmography or helium dilution). Measures of pulmo-
nary function were expressed as a percent of predicted for
correlative investigation. Paired t tests were used for
within group comparisons to examine the change in airway
morphology from baseline to time of diagnosis. Wilcoxon
sign rank test was used to compare direct measurements of
individual airways in a subset of 5 patients. p values less
than 0.05 were considered statistically significant. Analyses
were performed with SAS v. 9.1. (Carey, NC).Results
Eighty-eight of the 1854 subjects (4.7%) met our criteria for
BOS, 37 of which had one or more HRCT scans of sufficient
quality for analysis (total of 59 scans) Fig. 2. Of these 37
subjects, 33 had CT scans and PFTs within 30 days of each
other, meeting our inclusion criteria for cross sectional
analysis. The CT scans from the remaining 4 subjects were
excluded from correlative analysis with lung function but
were included in subsequent longitudinal radiologic exam-
ination. Of the 37 subjects, 17 had a pre and post diagnosis
HRCT scan available for pooled airway analysis using the
calculated SRWA Pi10 mm. Of the 37 subjects, 5 had a pre
and post diagnosis HRCT available for direct matched
airway analysis. We identified 6 patients who meet our
criteria for controls the median interval between the pre-
transplant and post transplant HRCT scan was 323 days
(range: 15e1826).
Baseline characteristics of the 37 subjects with HRCT
scans are reviewed in Table 1. The median age of the 37
subjects was 48 years (range: 20e67) at the time of HSCT.
The median interval between HSCT and diagnosis of BOS
was 517 days (range: 48e1582).
All subjects received either a myeloablative (nZ 21) or
reduced intensity conditioning (n Z 16) allogeneic HSCT1854 HSCT Patients
88 Cases of BOS
37 Patients with HRCT 
scans available for 
analysis
33 patients for cross 
sectional analysis
17 patients for
longitudinal analysis with 
pooled airways
5 Patients for
longitudinal analysis with 
matched airways
Figure 2 Flow chart detailing patient inclusion criteria for
analysis.
Table 1 Baseline characteristics of 37 patients with HRCT
scans.
Age in years 48 (range: 20e67)
Days from HSCT to diagnosis of
BOS
517 (range: 48e1582)
Gender (female) 19 (51.4)
Race (Caucasian) 31 (83.8)
History of smoking 18 (48.6)
BOS confirmed by pathologya 7 (18.9)
Chronic GVHD 36 (97.3)
History of asthma 7 (18.9)
History of COPD 1 (2.7)
Conditioning regimen for HSCTb
Myeloablative conditioning 21 (56.8)
Reduced intensity conditioning 16 (43.2)
Donor source
Matched unrelated 20 (54.1)
Matched related 9 (24.3)
Mismatched unrelated 8 (21.6)
Disease transplanted
AML 17 (45.9)
NHL 7 (18.9)
MDS 5 (13.5)
CML 4 (10.8)
ALL 2 (5.4)
HD 1 (2.7)
AA 1 (2.7)
Reason for post BOS diagnosis
scans
35 (92.1)
Clinical follow up 11 (31.4)
Cough/SOB/fever/hypoxemia 19 (54.3)
Abnormal prior imaging 1 (2.9)
a Of the 7 patients with BOS confirmed on pathology 2/7 did
not meet FEV1/FVC criteria for inclusion but all 7 subjects met
FEV1 inclusion criteria.
b Myeloablative conditioning regimens: cytoxan þ total body
irradiation 1400cGY; high dose Busulfan þ cyclophosphamide.
Reduced intensity conditioning regimen: fludarabine þ low dose
busulfan.
Table 2 Changes in pulmonary function after hemato-
poietic stem cell transplantation in our cohort of 37
subjects. Data is expressed as the average percent pre-
dicted (PP) and the standard deviations are in parenthesis.
The pre HSCT PFT’s were conducted prior to the patients
HSCT, the post BOS PFT’s are the first set of pulmonary
function tests that meet our diagnostic criteria for BOS.
Pre HSCT Post BOS D (Pre-Post)
FVC PP 93.7 (17.0) 68.8 (16.9) 24.9%
FEV1 PP 92.8 (15.9) 55.9 (16.0) 36.9%
FEV1/FVC 77.3 (9.6) 61.8 (10.0) 15.5%
TLC PP 95.9 (19.9) 80.4 (15.7) 15.5%
DLCO PP 84.4 (22.0) 63.7 (19.9) 20.7%
Table 3 Correlation coefficients (r Values) of the univar-
iate regression analysis for square root of wall area at Pi10
with pulmonary function tests, HRCT scan and PFT’s were
conducted  30 days of each other. n Z 25e33.
PFT r value p value
FVC PP 0.546 0.001
FEV1 PP 0.636 <0.0001
FEV1/FVC% 0.343 NS
FEF25e75% 0.578 0.0004
VC PP 0.595 0.002
IC PP 0.602 0.002
ERV PP 0.353 NS
TLC PP 0.219 NS
RV PP 0.561 0.002
RV/TLC PP 0.736 <0.0001
DLCO PP 0.175 NS
Airway dilation in bronchiolitis obliterans 279frommatched unrelated donors (nZ 20) or matched related
donors (n Z 9), or mismatched unrelated donors (n Z 8).
Transplantation was performed for acute myelogenous
leukemia (nZ 17), non-Hodgkin lymphoma (nZ 7), myelo-
dysplastic syndrome (n Z 5), chronic myeloid leukemia
(n Z 4), acute lymphoblastic leukemia (n Z 2), Hodgkin
lymphoma (nZ 1) and Aplastic anemia (nZ 1). A history of
any smoking prior to transplantation was reported by 48.6%
of subjects and 21.6% carried a pre HSCT diagnosis of either
COPD (nZ 1) or asthma (nZ 7). All subjects with a pre HSCT
history of COPD or asthma had non-reversible obstructive
deficits on bronchodilator challenge.
Baseline and follow up measures of pulmonary function
are presented in Table 2. As expected, after the diagnosis
of BOS there was a statistically significant decline in the
FEV1, FVC, FEV1/FVC ratio, DLco and a significant decrease
in TLC compared with similar values obtained prior to HSCT
(all p < 0.01).
Of the 37 subjects in our study, 35 subjects had HRCT
scans conducted after meeting inclusion criteria for BOS.We reviewed the clinical reports for these CT scans for
abnormal findings. Bronchiectasis was documented in 14
(40%), mosaic attenuation in 5 (14.3%), ground glass opac-
ities in 6 (17.1%), centrilobular nodules or nodules in 8
(22.9%), bronchial wall thickening in 2 (5.7%) and 26 (74.3%)
had at least one abnormal finding reported.
For the correlative studies, all HRCT scans with pulmo-
nary function testing available 30 days the SRWA Pi10 mm
was calculated. Table 3 depicts the relationship between
the SRWA Pi10 mm and multiple lung function parameters.
Fig. 3A and B depict the direct relationship between the
SRWA Pi10 mm and FEV1% predicted (n Z 33, r Z 0.636,
p < 0.0001) and the inverse relationship for RV/TLC% pre-
dicted (n Z 28, r Z 0.736, p < 0.0001) respectively, as
these two values were most significantly correlated with
SRWA Pi10 mm. In subsequent models adjusted for age, sex
and total lung capacity the SRWA Pi10 mm remained
a significant predictor of FEV1% predicted (p < 0.0001) and
RV/TLC% predicted (p < 0.0001).
Of the 37 subjects with HRCT scans available we iden-
tified 5 with HRCT images which allowed direct comparison
of anatomically matched individual airways at both time
points. In these selected airways, there was a trend for an
increase in the lung volume, internal lumen perimeter (PI),
and a decrease in wall area percent (WA%) (p Z 0.06,
Fig. 4B).
33.5
4
4.5
5
10 30 50 70 90 110 130
S
R
W
A
 
P
i
1
0
m
m
FEV
1
% predicted
p < 0.0001
r = 0.636
3
3.5
4
4.5
5
20 70 120 170 220
S
R
W
A
 
P
i
1
0
m
m
RV/TLC % predicted
B p < 0.0001
r = -0.763
A
Figure 3 A and B. Graphs of the relationship between square
root of wall area at Pi10 mm and each of the pulmonary
function parameters. Pulmonary function parameters are
expressed as a percentage of the predicted normal value. Each
graph is shown with a fitted regression line. The correlations (r)
and p values (p) were (A) FEV1 nZ 33 (rZ 0.636, p < 0.0001)
and (B) RV/TLC n Z 28 (r Z 0.736, p < 0.0001).
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subjects meeting our criteria for longitudinal analysis were
identified. For longitudinal studies HRCT scans were
included if the patient had at least two HRCT scans avail-
able; a pre diagnosis HRCT scan defined as being conducted
prior to transplantation or after HSCT but >120 days from
the diagnosis of BOS and an HRCT scan post diagnosis or
within 60 days of diagnosis of BOS. The SRWA Pi10 mm
significantly decreased from the pre-diagnosis HRCT scan
compared to the post diagnosis HRCT scan (p < 0.001).
There was no significant change in 6 control subjects who
had a pre transplant and post transplant HRCT scan avail-
able for analysis Fig. 5A.
Of the 17 subjects with HRCT scans conducted before and
after meeting inclusion criteria for BOS. We reviewed the
clinical reports for these CT scans for abnormal findings.
Bronchiectasis was documented in 6 of the 17 post diagnosis
CTscans (35%) while all 17 subjects had a decline in the SRWA
Pi10 mm from the pre to post BOS HRCT scan (100%).
We identified 8 subjects who had an HRCT scan >100
days after HSCT, but before the diagnosis of BOS. This
analysis allowed us to determine of the change in SRWA
Pi10 mm is independent of pre-transplant conditioning
regimen. As shown in Fig. 5B, the SRWA Pi10 mm was less in
the HRCT after the diagnosis of BOS as compared with the
HRCT that preceded the diagnosis of BOS (p < 0.001).
Based upon prior investigations of subjects with COPD,
we expected the Pi10 to be inversely related to a subject’s
degree of expiratory airflow obstruction (FEV1% predicted).
For example, in smokers, those with greater degrees ofexpiratory airflow obstruction tended to have increased
SRWA suggestive of airway wall thickening.16 In fact, the
directions of our correlations were opposite to this sug-
gesting that similar to what we observed in the 5 subject in
whom we could measure anatomically matched airways,
airways were dilating or that their walls were thinning
proportionally to the severity of BOS.Discussion
To our knowledge, this is the first study to use direct
quantitative measurement of the airway diameter before
and after the diagnosis of BOS. In our investigation of
clinically acquired HRCT scans, we found that airway
remodeling in BOS is characterized by central airway dila-
tion. The degree of this dilation, as assessed by the SRWA
Pi10 mm, was significantly associated with impairments in
lung function.
Previous investigation has demonstrated that airway
caliber is directly related to lung volume; specifically the
airways dilate with increasing lung volume.19 Our subset of 5
subjects anatomically with matched individual airways also
demonstrated a trend for an increase in lung volume,
increased PI and a decrease in WA%. However, our model
adjusted for age, sex and total lung capacity the SRWA
Pi10 mm remained a significant predictor of FEV1% and RV/
TLC%. This data suggests that airway dilation is not solely
explained by a change in lung volume. In addition, in patients
who develop BOS, our longitudinal data suggest that the
central airway morphology observed at the time of the clin-
ical diagnosis of BOS was due to airway dilation as evidenced
by the decline SRWA Pi10 mm from baseline measures.
To date the quantitative assessment of HRCT in BOS
associated with HSCT is limited. There is a more extensive
literature in the lung transplant population, but like the
HSCT population the vast majority of these studies are also
subjective rather than quantitative evaluations of HRCT
findings in BOS. The subjective studies in the BOS lung
transplantation population have provided mixed results
with regards to predictive ability of visual assessments of
air trapping and bronchial dilation in the diagnosis of
BOS.20e27 However, there are two studies assessing the
quantitative analysis of mean lung attenuation in patients
with BOS secondary to lung transplantation. Knollmann
et al. demonstrated that those with greater amounts of gas
trapping on expiratory CT were more likely to progress to
clinically overt BOS.28,29
Commonly reported HRCT findings in BOS after HSCT
include bronchiectasis, bronchial wall thickening, mosaic
attenuation and centri-lobular nodules.9e13 Of the 35 HRCT
scans conducted after the diagnosis of BOS bronchiectasis
was reported in 14 (40%), centri-lobular nodules/nodules in 8
(22.9%), mosaic attenuation in 5 (14.3%), bronchial wall
thickening in 2 (5.7%). Previous small studies of the HRCT
findings in BOS have reported the prevalence of bronchiec-
tasis to be between 11% and 71% of patients with BOS; the
criteria used to define bronchiectasis were the lumen diam-
eter being greater than that of the adjacent pulmonary
artery.10e13 The largest study by Gunn et al. documented
bronchiectasis to be present in 42% of their cohort, and we
found 40% of our cohort to have clinically identified
Figure 4 A. Representative images from HRCT scans of patient #5 before transplantation and after the diagnosis of BOS. Arrows
demonstrate airway dilation. B. Change in lung volume, internal lumen perimeter (PI), wall thickness and wall area % (WA%) from
before and after the diagnosis of BOS in 5 patients with anatomically matched airways on HRCT scans.
Airway dilation in bronchiolitis obliterans 281bronchiectasis. These data suggest that our cohort is repre-
sentative of prior BOS cohorts. In addition, we were able to
document a decline in the SRWA Pi10 mm in all 17 subjects
meeting our criteria for longitudinal analysis. While the
clinical reports only identified bronchiectasis in 6 of the 17
subjects (35%). These data suggest that either bronchiectasis
is underreported or that quantitative airway measurements
may be more sensitive in detecting airway dilation.
Studies in COPD and asthma have demonstrated that
quantitative measure of proximal airway wall thickening
correlate with pulmonary function.17,30,31 However, our
results are the opposite of those found in patients with
COPD where a decrease in FEV1 is associated with an
increase of the airway wall area.31 Our analysis suggeststhat the change in lumen diameter associated with the
development of BOS is not solely explained by the increase
in lung volume in our cohort of subjects with BOS. These
findings support the hypothesis that airway remodeling,
resulting in bronchial dilation, is occurring in patients with
BOS.
One possible explanation for the difference between the
findings in COPD and asthma can be explained by the
pathologic findings in BO described by Yousem. Yousem32
reviewed the largest series of 17 patients with graft
versus host disease of the lung. He suggested that there is
a spectrum and progression of airways pathology from
lymphocytic bronchitis/bronchiolitis affecting both large
and small airways to the lymphocytic bronchitis/
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Figure 5 A. Seventeen patients with HRCT scans obtained
both before and after the diagnosis of BOS (p < 0.001) and 6
control patients who did not develop airflow obstruction with
HRCT scans obtained both before and after transplant
(p Z NS). B. Eight patients with HRCT scans obtained more
than 100 days after HSCT as well as an HRCT after the diagnosis
of BOS (p < 0.003).
282 L. Gazourian et al.bronchiolitis with intraluminal granulation tissue and cica-
tricial bronchiolitis obliterans found in the distal airways.
He hypothesized that the bronchiolitis obliterans repre-
sented the late and potentially irreversible stage of the
disease; subsequent case series and reports have confirmed
Yousem’s findings.33,34 The early lymphocytic bronchitis/
bronchiolitis found in patients with cGVHD of the lung may
result in airway remodeling and dilation and that the
greater the degree of proximal airway dilation is simply an
indicator of more peripheral airway disease and oblitera-
tion. This is further supported by the findings of Glanville
et al.35 who demonstrated that lymphocytic bronchiolitis is
associated with an increased risk of BOS after lung trans-
plantation and by Sugino et al.36 who demonstrated, using
histopathological bronchial reconstruction, proximal airway
dilation in a case series of patients with bronchiolitis
obliterans.
One of the major limitations of our study is that we
performed a secondary analysis of clinically acquired data.
With regard to the CT imaging, the lack of volumetric
reconstructions did not allow us to compare anatomically
matched airways over time in our cohort. We were limited
to 5 subjects who had HRCT scans that had anatomically
matched airways. We feel that the trend toward signifi-
cance in this small cohort is impressive, and the modest p
value of 0.06 very likely results from low power. We hope to
replicate these findings is a larger prospective cohort soon.
Although this is a limitation of our current study, it also
represents the significant potential of quantitative airway
analysis and the diagnosis of BOS.
Our results and the work of Knollmann et al. suggest that
quantitative HRCT scans may provide a new and promising
modality for the prospective identification of BOS prior to
symptoms and the development of a significant decline inpulmonary function. Further work is needed to determine
the etiology of these radiologic changes in the central
airways and if these observed changes can be used to
predict the development of BOS.
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